LifeMD price target raised to $18 from $15 on GLP-1 demand at BTIG

BTIG raised its price target on LifeMD (LFMD) to $18 from $15, maintaining a Buy rating, citing strong demand for obesity health services and GLP-1 medications. This follows positive meetings with management and LifeMD's recent Q1 2025 results, which included a 49% revenue increase to $65.7 million and its first positive EPS of $0.01, leading to raised full-year revenue guidance of $268-$275 million. BTIG believes LifeMD's earnings may exceed expectations through 2025, driven by continued demand for GLP-1s and diversification into new service lines, though InvestingPro data suggests the stock is trading above its Fair Value.

Analysis

BTIG's upgraded price target for LifeMD Inc. (NASDAQ:LFMD) to $18 from $15, while maintaining a Buy rating, reflects heightened analyst confidence driven by robust demand for obesity health services and GLP-1 medications, alongside positive investor sentiment following meetings with company management. This optimism is substantially supported by LifeMD's strong Q1 2025 financial results, which featured a 49% year-over-year revenue surge to $65.7 million, the achievement of its first positive earnings per share at $0.01 (beating expectations of -$0.0583), and a subsequent increase in full-year revenue guidance to between $268 million and $275 million. The company demonstrates solid fundamentals with an impressive 88% gross profit margin and 43% revenue growth over the last twelve months to $234 million, reportedly with customer acquisition costs under control. LifeMD is actively diversifying its service offerings into areas like Hormone Replacement Therapy, mental health, and women's health, and has established important pharmaceutical partnerships, including a collaboration with Novo Nordisk for a weight management bundle. Despite the stock's significant 162% appreciation over the past six months, placing it near its 52-week high, InvestingPro data indicates it may be trading above its calculated Fair Value, warranting investor attention. Furthermore, the potential near-term sale of LifeMD’s WorkSimpli business division, as indicated by management, could also influence the company's strategic direction and financial profile.

Key Decisions for Investors

• Investors should consider LifeMD's strong growth trajectory fueled by the GLP-1 market and its recent Q1 2025 outperformance, including its first positive EPS and upwardly revised full-year guidance, which underpins the bullish analyst outlook.
• It is prudent to carefully monitor the stock's valuation, as InvestingPro suggests it may be trading above its intrinsic fair value, despite the company's high gross profit margins and significant revenue expansion.
• Assess the strategic benefits and potential financial impact of LifeMD's diversification into new healthcare service lines and the possible divestiture of its WorkSimpli business unit.